Abstract
Development of targeted radionuclide therapy with 90Y labeled antibodies and peptides has gained momentum in the past decade due to the successes of 90Y-ibritumomab tiuxetan and 90Y-DOTA-Phe1-Tyr3-octreotide in treatment of cancer. 90Y is a pure β--emitter and cannot be imaged for patient-specific dosimetry which is essential for pre-therapeutic treatment planning and accurate absorbed dose estimation in individual patients to mitigate radiation related risks. This review article describes the utility of 86Y, a positron emitter (33%) with a 14.7-h half-life that can be imaged by positron emission tomography and used as an isotopically matched surrogate radionuclide for 90Y radiation doses estimations. This review discusses various aspects involved in the development of 86Y labeled radiopharmaceuticals with the specific emphasis on the radiochemistry and biological applications with antibodies and peptides.
Keywords: PET imaging, radiochemistry, 90Y, 86Y, bioconjugate chemistry, peptides, antibodies, positron emitter, Radiopharmaceuticals, targeted radionuclide therapy
Medicinal Chemistry
Title: 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Volume: 7 Issue: 5
Author(s): Tapan K. Nayak and Martin W. Brechbiel
Affiliation:
Keywords: PET imaging, radiochemistry, 90Y, 86Y, bioconjugate chemistry, peptides, antibodies, positron emitter, Radiopharmaceuticals, targeted radionuclide therapy
Abstract: Development of targeted radionuclide therapy with 90Y labeled antibodies and peptides has gained momentum in the past decade due to the successes of 90Y-ibritumomab tiuxetan and 90Y-DOTA-Phe1-Tyr3-octreotide in treatment of cancer. 90Y is a pure β--emitter and cannot be imaged for patient-specific dosimetry which is essential for pre-therapeutic treatment planning and accurate absorbed dose estimation in individual patients to mitigate radiation related risks. This review article describes the utility of 86Y, a positron emitter (33%) with a 14.7-h half-life that can be imaged by positron emission tomography and used as an isotopically matched surrogate radionuclide for 90Y radiation doses estimations. This review discusses various aspects involved in the development of 86Y labeled radiopharmaceuticals with the specific emphasis on the radiochemistry and biological applications with antibodies and peptides.
Export Options
About this article
Cite this article as:
K. Nayak Tapan and W. Brechbiel Martin, 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications, Medicinal Chemistry 2011; 7 (5) . https://dx.doi.org/10.2174/157340611796799249
DOI https://dx.doi.org/10.2174/157340611796799249 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Targeting MUC15 Protein in Cancer: Molecular Mechanisms and Therapeutic Perspectives
Current Cancer Drug Targets C60 Fullerene Derivatized Nanoparticles and their Application to Therapeutics
Recent Patents on Nanotechnology Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Genotoxicity of Nanocarriers
Current Drug Metabolism The Human Pseudoautosomal Region (PAR): Origin, Function and Future
Current Genomics Research and Development of Nuclear Molecular Imaging in Taiwan
Current Medical Imaging Synthesis and Anticancer Study of Novel 4H-Chromen Derivatives
Anti-Cancer Agents in Medicinal Chemistry Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Current Medicinal Chemistry Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Cutaneous Markers of HIV Infection and Progression
Current HIV Research Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study
Combinatorial Chemistry & High Throughput Screening Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine